Faculty:
Andrew A. Moshfeghi, MD, MBA
Associate Professor of Clinical Ophthalmology
Director Clinical Trials Unit
USC Eye Institute
University of Southern California
Keck School of Medicine
Los Angeles, CA
Reviewer:
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 6/3/2019)
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Faculty member reports the following relationship(s) which are accurate at the time of original content release (June 13, 2016):
Andrew A. Moshfeghi, MD, MBA
Consulting Fees: Alimera Sciences, Inc.; Allergan, Inc.; Genentech, Inc.; Optos; ThromboGenics
Contracted Research: Genentech, Inc.; Regeneron Pharmaceuticals, Inc.
Ownership Interest: OptiSTENT, Inc.
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.